Makers Laboratories Limited concluded its 41st Annual General Meeting (AGM) on August 7, 2026, with shareholders approving the adoption of audited financial statements for the fiscal year ended March 31, 2026. The meeting, conducted through Video Conferencing / Other Audio Visual Means (VC/OAVM), also saw the ratification of remuneration for statutory auditors and approval of specific related party transactions. This procedural milestone ensures regulatory compliance under the Companies Act, 2013, and SEBI listing obligations.

The meeting commenced at 12:30 p.m. and was presided over by Chairman R. K. P. Verma. All directors, the Chief Executive Officer, Chief Financial Officer, and Company Secretary were present. Representatives from the Statutory Auditors, Secretarial Auditors, and the Scrutinizer also attended via video conference. The Chairman confirmed that the quorum was present throughout the proceedings. He informed members that statutory registers and documents related to the agenda items were available for inspection on the company’s website.

Voting Process and Scrutiny

Pursuant to Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company facilitated electronic voting. The remote e-voting window remained open from August 3, 2026, to August 6, 2026, with a cut-off date of July 31, 2026, to determine eligible shareholders. Ms. Jigyasa N. Ved of M/s. Parikh & Associates was appointed as the Scrutinizer to oversee the e-voting process. Shareholders present at the virtual meeting who had not voted remotely were given an additional 15 minutes to cast their votes during the session.

Resolutions Approved

The shareholders voted on several ordinary resolutions covering both ordinary and special business. There were no adverse remarks or qualifications in the Independent Auditors Report or Secretarial Audit Report, so these reports were not read out in detail.

Mr. Saahil Parikh (DIN 00400079), who retires by rotation, was re-appointed as a Director. The special business included approving related party transactions with Ipca Laboratories Ltd., a related party entity. Additionally, the shareholders ratified the remuneration of ₹1,50,000 payable to M/s. Poddar & Co., Cost Accountants (Firm Registration No. 101734) for the financial year 2026-27.

Conclusion

Following the voting process, the Whole-time Directors responded to queries raised by members. The e-voting module was kept open for the final 15 minutes before the meeting was deemed closed at 1:30 p.m. The final results of the voting will be declared upon receipt of the scrutinizer’s report and will be displayed on the company’s website and notice board at its registered office in Mumbai.

What the Numbers Show

The absence of adverse remarks in the audit reports indicates a clean compliance status for the fiscal year ended March 31, 2026. The ratification of cost accountant remuneration at ₹1,50,000 for FY27 reflects standard operational governance. The approval of related party transactions with Ipca Laboratories Ltd. suggests ongoing strategic or operational synergies between the entities, requiring shareholder oversight as per regulatory norms.

Makers Laboratories Limited reported its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at their meeting held on August 7, 2026 in Mumbai. On a consolidated basis, the company delivered a notable improvement in profitability, while the standalone pharmaceutical business continued to face headwinds, recording a net loss for the quarter.

Consolidated Financial Performance

The consolidated results reflect a strong performance, driven primarily by the Chemical Manufacturing segment. Consolidated revenue from operations grew to ₹4,277.16 lacs in Q1FY27, compared to ₹3,500.10 lacs in Q1FY26 and ₹3,575.17 lacs in Q4FY26. Total consolidated income stood at ₹4,338.09 lacs for the quarter. Net profit attributable to owners of the parent surged to ₹150.43 lacs from ₹43.67 lacs in Q1FY26, representing a significant year-on-year improvement. Basic and diluted earnings per share (not annualised) stood at ₹2.55 for Q1FY27, compared to ₹0.74 in Q1FY26.

The following table summarises the key consolidated financial metrics:

Standalone Financial Performance

The standalone results pertain solely to the pharmaceutical business of Makers Laboratories. Revenue from operations declined to ₹1,018.75 lacs in Q1FY27 from ₹1,372.68 lacs in Q1FY26 and ₹1,127.46 lacs in Q4FY26. Total standalone income was ₹1,025.90 lacs for the quarter. The standalone business recorded a net loss of ₹107.50 lacs for Q1FY27, widening from a net loss of ₹27.20 lacs in Q1FY26. Total standalone expenses amounted to ₹1,151.62 lacs, against total income of ₹1,025.90 lacs. Basic and diluted EPS (not annualised) stood at ₹(1.82) for Q1FY27.

Segment Performance

The group operates across two reportable segments — Pharmaceutical and Chemical Manufacturing. The Chemical Manufacturing segment, operated through subsidiary Resonance Specialties Limited, was the primary driver of consolidated profitability. The subsidiary reported total revenue (including other income) of ₹3,312.19 lacs and total net profit after tax (including OCI) of ₹574.46 lacs for Q1FY27.

The segment-wise breakdown for Q1FY27 is as follows:

Board Composition and Directorship Changes

The Board also announced a change in directorship during the meeting. Mr. Saahil Parikh (DIN 00400079), whose term as Whole-time Director & CEO concludes on August 10, 2026, has informed the Board that he does not wish to be re-appointed in that capacity due to personal and professional reasons. He confirmed there are no other material reasons for this decision. The Board has appointed him as a Non-Executive, Non-Independent Director with effect from August 11, 2026, subject to shareholder approval. Mr. Parikh, aged 51 years, holds a graduation in Bio-Chemistry from Gujarat University and a Diploma in Management Studies from Ahmedabad Management Association, with approximately 25 years of experience in the pharma industry.

Following this change, the revised Board composition effective August 11, 2026 is as under:

The Board also reconstituted the Stakeholders Relationship Committee and the Risk Management Committee in light of the directorship changes. The financial results were prepared in accordance with Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013, and the statutory auditors, N V C & Associates LLP, issued an unmodified limited review report on both the standalone and consolidated results.